interaction records 54 assistance programs 55 0 personal data stored
OmniRx › Tools › Generic competition check › Selexipag

Generic competition · all medicines · read 12 November 2026

Is there a generic of Selexipag, and who makes it?

Selexipag appears in 2 dosage-form groups in the FDA Orange Book as of 12 November 2026, with 2 generic makers listed as marketed across them. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming. Where both are dated, the first generic approval came 7 years after the first brand approval. This is the Orange Book's listing, not a forecast.

Compiled and checked by Vincent Wesley Couey (ORCID 0009-0005-6869-308X) from the Orange Book data files, downloaded 12 November 2026.

Not medical advice. This page reports what the FDA's Orange Book lists, not what a pharmacy has in stock, what anything costs, or whether a generic is right for you. Ask your pharmacist or prescriber about your own medicine.
Selexipag2 dosage-form groups in the Orange Book
2generic makers listed
  1. Selexipag appears in 2 dosage-form groups in the FDA Orange Book as of 12 November 2026, with 2 generic makers listed as marketed across them.
  2. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming.
  3. Where both are dated, the first generic approval came 7 years after the first brand approval.
  4. Patents and exclusivities are shown as listed by the application holder; the Orange Book does not rule on them, and a listed patent is not a statement that a generic is blocked. This says nothing about price, supply or quality.

Tablet, Oral

One to three generic makers listed

Brand listed as marketed: Uptravi. 2 generic makers with 14 generic products listed as marketed; the first generic approval is dated 21 December 2022.

20152020202520302035204002brand 2015Alembic Pharmaceuticals Ltd, first approval 11 October 2023Rk Pharma Inc, first approval 16 April 2026data datePatent 7205302*PED listed to expire 30 April 2027Patent 9173881 listed to expire 12 August 2029Patent 9173881*PED listed to expire 12 February 2030Patent 9284280 listed to expire 25 June 2030Patent 8791122 listed to expire 1 August 2030Patent 9284280*PED listed to expire 25 December 2030Patent 8791122*PED listed to expire 1 February 2031Patent 10828298 listed to expire 1 December 2036Patent 10821108 listed to expire 1 December 2036Patent 10821108*PED listed to expire 1 June 2037Patent 10828298*PED listed to expire 1 June 2037Exclusivity NS to 23 May 2029Exclusivity NPP to 23 May 2029Exclusivity PED to 23 November 2029
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end
Generic maker (applicant)First approvalProducts
Alembic Pharmaceuticals Ltd11 October 20236
Rk Pharma Inc16 April 20268

Patents and exclusivities still listed

  • 23 May 2029Exclusivity NS Uptravi
  • 23 May 2029Exclusivity NPP Uptravi
  • 23 November 2029Exclusivity PED Uptravi
  • 30 April 2027Patent 7205302*PED
  • 12 August 2029Patent 9173881
  • 12 February 2030Patent 9173881*PED
  • 25 June 2030Patent 9284280
  • 1 August 2030Patent 8791122 drug substance
  • 25 December 2030Patent 9284280*PED
  • 1 February 2031Patent 8791122*PED
  • 1 December 2036Patent 10828298 drug product

3 more patents are listed.

Powder, Intravenous

Brand listed, no generic listed as marketed

Brand listed as marketed: Uptravi. No generic is listed as marketed.

202020252030203501brand 2021data datePatent 7205302*PED listed to expire 30 April 2027Patent 9173881 listed to expire 12 August 2029Patent 9173881*PED listed to expire 12 February 2030Patent 9284280 listed to expire 25 June 2030Patent 8791122 listed to expire 1 August 2030Patent 9284280*PED listed to expire 25 December 2030Patent 8791122*PED listed to expire 1 February 2031
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

  • 30 April 2027Patent 7205302*PED
  • 12 August 2029Patent 9173881
  • 12 February 2030Patent 9173881*PED
  • 25 June 2030Patent 9284280
  • 1 August 2030Patent 8791122 drug substance
  • 25 December 2030Patent 9284280*PED
  • 1 February 2031Patent 8791122*PED

US Food and Drug Administration, Orange Book data files, downloaded 12 November 2026. A listed patent is not a ruling that a generic is blocked, and no figure here says anything about price, supply or quality. Check the Orange Book.

Where can you go from this result?

Open it in the check to search another medicine, or see every brand with no generic listed. The FDA explains generic approval in how generic drugs are approved and the FDA generic drug facts, and the Orange Book itself is the FDA Orange Book. To check what is available now, ask your pharmacist, and see the FDA drug shortages page.